Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in SARD-ILD
jRCT2071240117Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in connective tissue disease-associated interstitial lung disease (CTD-ILD) and interstitial lung disease (ILD) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Absolute change from baseline in quantitative interstitial lung disease score at Week 26. Started Aug 2025; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCT2071240117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240117.